San Diego-based Amylin Pharmaceuticals Inc. said Jan. 27 that the U.S. Food and Drug Administration approved its drug Bydureon, the first once-weekly injection to treat type 2 diabetes.
Shares of the publicly traded company jumped more than 17 percent to $14.23 in after-hours trading on Nasdaq after closing at $12.14.
The drug, which controls blood-sugar levels, will be in pharmacies in February, Amylin said, in a joint statement with Dublin, Ireland-based development partner Alkermes Plc.
Post Continues on www.sdbj.com